Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences
September 08, 2017
Dr Patricia Danzon: Learning From European Health Systems
August 30, 2017
Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work
August 23, 2017
Dr Patricia Danzon Highlights European Examples of Restraining Drug Prices
August 16, 2017
Dr Ilene Hollin Outlines Differing Definitions of Value
August 09, 2017
Dr Patricia Danzon: Cost Effective Doesn't Mean Affordable
August 03, 2017
Dr Michael Sherman on Performance-Based Risk-Sharing Agreements
July 28, 2017
Currently Reading
Dr David Cutler Assesses the Political Odds of Drug Pricing Reform
July 25, 2017
Dr Gail Wilensky: Increased Competition a Better Drug Pricing Solution Than Cost Controls
July 16, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017

Dr David Cutler Assesses the Political Odds of Drug Pricing Reform

Legislators from both parties may have difficulty finding a common solution to high drug prices, but President Donald Trump could be instrumental in bringing prices down if he acts on his pledges, according to David M. Cutler, PhD, of Harvard University.


Legislators from both parties may have difficulty finding a common solution to high drug prices, but President Donald Trump could be instrumental in bringing prices down if he acts on his pledges, according to David M. Cutler, PhD, of Harvard University.

Transcript (slightly modified)

Drug pricing is one area that Democrats and Republicans both agree on. Do you think they might be able to pass legislation addressing rising drug costs? What might it look like?

On drug costs, as with everything in healthcare, the best guess is always no change. I think both Democrats and Republicans are upset that there are people who can’t afford medications, but what they would do about it is very different, and therefore, the ability to compromise is going to be difficult here.

There are things they can do about the FDA, and they’re sort of doing a little bit of that, but the other major issues about things like prices of new medications, price increases, how much you can charge people who are uninsured, things like that, I don’t see a lot of agreement upon.

I think the wild card here is the President, whose sympathies on this seem to lie much more with the Democrats than with the Republicans. So if he decided he really wanted to do something there and he was going to work with the Democrats and bring things along, he really could force the issue more. I don’t know whether he will. So far, he’s governed as a very, very traditional right-wing Republican, and so if that’s the way he’s going to go, the odds that things happen will be very low.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!